VIDEO: IL-23 inhibitor demonstrates high efficacy in FRONTIER-2 study
Click Here to Manage Email Alerts
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the FRONTIER-2 study.
Chovatiya, clinical associate professor at Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, spoke about the efficacy and safety of the oral interleukin-23 inhibitor JNJ-2113 (Johnson & Johnson, Protagonist Therapeutics) in the treatment of psoriasis, which showed promising results.
“We are looking at [a mechanism of action] that we’ve really only seen in the case of biologic therapy in an oral therapy, and efficacy that is really even stretching beyond what we were previously been seeing, maybe teetering around a generation one biologic,” Chovatiya said.
Collapse
Read more about
Click Here to Manage Email Alerts